首页/数据集/Effect of Silymarin in Metastatic Colorectal Cancer Patients

Effect of Silymarin in Metastatic Colorectal Cancer Patients

NIAID Data Ecosystem2026-03-14 收录

转移性结直肠癌治疗

药物疗效评估

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/879 数据链接链接失效反馈

官方服务：

资源简介：

this work is aim to assess the antitumor effect of silymarin in patients with metastatic colorectal cancer receiving chemotherapy with or without target therapy (Bevacizumab).

应用场景：

创建时间：

2022-12-15

相关数据集

PRISMA XA Checklist and Diagram

药物疗效评估

静脉血栓管理

Prisma Checklist for Factor Xa Inhibitor For Venous Thromboembolism Management In Patient With Cancer: A Sysytematic Review And Meta-analysis

Figshare2021-11-12 更新120

Datasets for Article: Active Learning for Medical Article Classification with Bag of Words and Bag of Concepts Embeddings

医学文献分类

药物疗效评估

The file 'cases.zip' contains data for 15 case studies used in the experiments discussed in the paper, see 'readme' file for the description how to use the data.The file 'python scripts.zip' is the co

Zenodo2025-06-14 更新40

FORECAST 1. Feasibility of using Organoid Response to find Effective Treatments for patients with Colorectal cancer After failure of Standard Therapy

类器官药物筛选

转移性结直肠癌治疗

Interventions: This feasibility study involves the collection of fresh tumour tissue from patients with Metastatic Colorectal Cancer ( mCRC) for the purposes of establishing organoid model cultures.Pa

NIAID Data Ecosystem40

Data_Sheet_1_Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs.pdf

肢端肥大症治疗

药物疗效评估

Introduction: Acromegaly is a rare, serious endocrine disorder characterized by excess growth hormone (GH) secretion by a pituitary adenoma and overproduction of insulin-like growth factor I (IGF-I).

NIAID Data Ecosystem60

Asthma control in NYUBAR groups (N = 471).

哮喘临床管理

药物疗效评估

Data missing for daytime symptoms on 1 subject, nocturnal symptoms in 2 subjects, SABA use in 15 subjects, functional status on 12 subjects.†Only 2 subjects used omalizumab: 1 in Group 2 and 1 in Grou

Figshare2015-12-02 更新40